The FDA gave final approval to Teva Pharmaceuticals to beg m marketing fenofibrate capsules (micronized) 67 mg for people with very high triglyceride levels. The 67-mg strength, the generic equivalent of Abbott's Tricor capsules, is the third version of the medication for which Teva has obtained FDA approval. In April, the FDA gave the green light for 134-mg and 200-mg dosages. Teva is entitled to 180 days of marketing exclusivity as the first company to file an ANDA for the drug.
Teva also announced it had received FDA approval to market cefaclor extended-release tablets, 75 mg and 500 mg, the generic equivalent of Eli Lilly's Ceclor CD (which Elan markets).
COPYRIGHT 2002 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2002 Gale Group